Rohan Katipally

Thrilled to present our work in @JAMAOnc!! 3 molecular subtypes of colorectal liver metastases and an integrated clinical-molecular risk stratification are prognostic in a phase III trial -- presenting a novel framework to stage metastatic disease Tweetorial below 👇

📢Excited for this case-based multidisciplinary meeting @UCCancerCenter discussing innovation and treatment optimization for #hncsm!🩺🧬🔬🩻 @HeadNeckMD @ajuloorimd @williamgaomd @your_hemoncdoc @DrUppaluri @NouraChoudhury @lab_pearson @DrJLorch @DanielOlsonMD @headandneckdoc

Proud of superstar resident, Dr. Abed Kawakibi @AbedKawakibi, presenting how ctDNA may improve surveillance of HPV+ oropharyngeal cancer after chemoradiation at @ASTRO_org — work emerging from treatment de-escalation protocols at our UChicago Head & Neck Cancer Program!

🧐Our DEPEND trial is out! Neoadjuvant nivo/chemo followed by response-stratified CRT in HPV-negative stage IVa/b HNSCC. @UCCancerCenter @UChicagoHemOnc @ajuloorimd @lab_pearson @HNCancerDoc @EIzumchenko @eevokes jamanetwork.com/journals/jamao…

Check out the latest from @UCCancerCenter HN Group - the DEPEND trial. 1) There is strong interest in determining how to incorporate immunotherapy into non-operative management for LA-HNSCC to improve outcomes for high risk HPV-negative patients.

Sharing the Burden: The Case for Definitive Local Therapy in Place of Immune Checkpoint Blockade for Patients With a Low-Volume Burden of Metastatic Disease: ascopubs.org/doi/10.1200/JC… @ConnorLynchMD @MuzamilArshad18 @RohanKatipally @rweichselbaum @UCCancerCenter

Could we hold off on checkpoint inhibitors in patients with low-volume metastatic disease and treat with local therapy instead? Our editorial exploring this idea: ascopubs.org/doi/10.1200/JC… (thanks to @rweichselbaum @MuzamilArshad18 @RohanKatipally @SeanPitroda)

@UChicagoMed We also want to give a shout out to the residents from the class of 2028 who will be joining us this summer: Abed Rahman Kawakibi, Sophia Kim-Wang, and Ryan Zitter! #match2024 #RadOnc #GME #matchday2024

Happy #matchday2024! We are thrilled to introduce our Class of 2029: Farris Jaamour, Mira Patel, and Montserrat Quintana! #RadOnc #GME @UChicagoMed #match2024

Our review titled: SBRT for Liver Tumors: What the Interventional Radiologist Needs to Know, is out now! Many thanks to my talented colleagues @RohanKatipally, @MichaelGutmanMD, and Dr. Koshy. Link: thieme-connect.com/products/ejour…

We could not be more proud that @yhasanUCradonc has been named UChicago Program Director of the Year! #GME #MedEd #RadOnc #Residency #Match @UChicagoGME

How can radiation cause immunosuppressive changes to the TME and promote a "badscopal" effect? Happy to contribute to this review led by Liangliang Wang discussing some possible mechanisms! authors.elsevier.com/c/1iDg2_yeTfNc… @rweichselbaum @SeanPitroda @UCCancerCenter @UChicagoRadonc

Last night we had a celebration of Dr Gooi and his service to our section! He’ll be heading to Malaysia 🇲🇾 in December for his next chapter and we wish him all the best! He’ll be sorely missed as a dedicated clinician and educator #ENT #IamOto #MedTwitter #HNOncology

Our data presented at #ESMO23 suggests ctHPVDNA dynamics during neoadjuvant chemotherapy in context of response-adaptive de-escalation may be an early indicator of treatment effectiveness, along with as a surveillance strategy to detect and monitor recurrent disease.

Very excited to have aspiring Radiation Oncologists @MontseQ21 MS4 (@UToledoMed) and @lfspurr MS4 (@UChiPritzker) rotate with us at UCMC #RadOnc. #GME #UME #MedEd

In our #AskAScientist series on promising areas of cancer research for those starting their scientific careers, Ludwig @UChicagoMed’s Ralph Weichselbaum highlights bioinformatic analysis as a key skill for future researchers.

🎙️ Molecular subtypes of #colorectal liver metastases are prognostic ‼️@OncoAlert @JAMAOnc 📌Retro analysis Ph 3 New EPOC trial 240 👥w/ liver metastases - 🔍 Discovery (93 👥) & Validation cohort (147 👥) - 💉 Interventions: RNA sequencing & microRNA profiling 🥇🎯:Validate molecular subtypes in colorectal liver metastases - PFS & OS 📊RESULTS 👉Molecular subtypes: Canonical, Immune, Stromal 👉Immune subtype ⬆️ PFS & OS rates 👉Adding molecular subtypes ⬆️ predictive ability 👉Low-risk integrated group had ⬆️PFS & OS rates ✖️high-risk group #colorectalcancer #radonc #livermetastases

Great paper - congrats! Biomarkers needed to risk stratify in liver oligometastatic CRC & select for patients who might benefit most from SBRT. Furthermore, there is also data on presence of liver mets being immunosuppressive & poorly responsive to IO - but that adding SBRT could potentially be immunostimulatory. Could the risk groups in this study also be predictive of benefit to SBRT/IO combo?

📣Just published: Sean Pitroda, MD (@SeanPitroda) and colleagues published a new study in @JAMAOnc validating the #biomarkers for predicting outcomes for #colorectalcancer patients with liver metastasis. @UCCancerCenter @UChicagoMed @UChicagoRadonc ow.ly/aJRN50Pho77

Molecular subtypes of colorectal liver mets & an integrated clinical-molecular risk stratification are prognostic in this independent validation within New EPOC phase III randomized trial, offering a framework to stage metastatic disease ja.ma/3pTecRx #CRCSM #GICSM

Really interesting work on the biological heterogeneity of liver metastases in colon cancer. Gets to the broader concept of predicting prognosis based on clinical & biomarker profiles of pts who all fit under the heading of metastatic cancer but show different patterns.